Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy.

(Reuters) - Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The vaccine, currently in phase 3 trials, targets extraintestinal pathogenic Escherichia coli or ‘ExPEC’, which is estimated to cause around 10 million cases of invasive disease every year and ...

Sanofi and Johnson & Johnson are ending a Phase 3 study of an experimental E. coli vaccine after it failed to show a significant benefit over placebo in a review by an independent monitoring board.

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...

a rHEV vaccine expressed in E. coli (23 kDa and HEV 239 vaccine), a rHEV vaccine expressed in insect Sf9 cells via recombinant baculovirus (56 kDa), a rHEV-VLP vaccine with oral administration (50 ...

E. coli bacteria could be used to create biodegradable plastics, reports a paper published in Nature Chemical Biology. The ...

Their mRNA vaccine against uropathogenic E. coli could reduce antibiotics usage by preventing recurrent urinary tract infections. CureVac’s non-respiratory infectious disease program targets ...